Clinical Trial Update: Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of talazoparib in combination with the HSP90 inhibitor AT13387 for metastatic advanced solid tumors and recurrent ovarian, fallopian tube, prima…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• AT13387 (Onalespib) (onalespib)
• Talazoparib (Talzenna) (talazoparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Status: WITHDRAWN